Kepler Capital Maintains a Hold Rating on GSK plc (GSK)

Group 1 - GSK plc (NYSE:GSK) is considered one of the best growth stocks under $50 to buy now, with a Hold rating and a price target of £1,500.00 set by Kepler Capital [1] - For fiscal Q2 2025, GSK reported total sales of £8.0 billion, with a 33% increase in total operating profit and a 35% increase in total EPS, attributed to lower CCL charges [2] - The company generated £2.4 billion in cash from operations and reported free cash flow of £1.1 billion [2] Group 2 - GSK, formerly known as GlaxoSmithKline, is a global healthcare and biopharmaceutical corporation based in the UK, with a portfolio of over 20 vaccines and a focus on vaccines, immunology, and respiratory therapies [3] - The company is also involved in developing cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer, among other drugs [3]